AstraZeneca's Experimental Therapy Stumbles In Late-Stage Study For Rare Protein Deposit Condition

On Wednesday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the Cardiac Amyloid Reaching for Extended Survival (CARES) Phase 3 program.

The trial showed that anselamimab, a light chain depleter antibody, did not achieve statistical significance for the primary endpoint compared to placebo in patients with Mayo stages IIIa and IIIb light chain (AL) amyloidosis.

The primary endpoint was a hierarchical combination of time to all-cause mortality (ACM) and frequency of cardiovascular hospitalizations (CVH). All patients in the clinical program received a background standard of care for plasma cell dyscrasia.

Also Read: AstraZeneca In $15 Billion Talks For Drug That Could Upend Lung Cancer Treatment

Anselamimab showed highly clinically meaningful improvement in time to ACM and frequency of CVH in a prespecified subgroup of patients, compared to placebo.

Light chain ...